Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited

Transl Lung Cancer Res. 2023 Feb 28;12(2):200-203. doi: 10.21037/tlcr-22-899. Epub 2023 Jan 19.

Authors

Marc G Denis¹, Guillaume Herbreteau¹, Elvire Pons-Tostivint²

Affiliations

¹ Nantes Université, CHU Nantes, Department of Biochemistry, INSERM, CNRS, Immunology and New Concepts in Immunotherapy, Nantes, France.
² Nantes Université, CHU Nantes, Department of Medical Oncology, Nantes, France.

No abstract available

Keywords: Minimal residual disease (MRD); circulating tumor DNA (ctDNA); non-small cell lung cancer (NSCLC).

Publication types

Editorial
Comment